[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624828":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":27,"centralContacts":36,"locations":42,"responsibleParty":54,"collaborators":27,"id":56,"slug":27,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":27,"enrollmentInfo":65,"targetDuration":27,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":77,"overallStatus":82,"whyStopped":27,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Centre Hospitalier Universitaire, Amiens","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Group","ACTIVE_COMPARATOR","Laparoscopic port-site infiltration with Ropivacaine Alone (No IV Lidocaine)",[13,14],"Drug: Procedure\u002FStandard care","Drug: ropivacaine",{"label":16,"type":17,"description":18,"interventionNames":19},"Experimental group","EXPERIMENTAL","IV Lidocaine + laparoscopic port-site infiltration with Ropivacaine",[13,14,20],"Drug: Lidocaine (intravenous infusion, perioperative)",[22,28,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Procedure\u002FStandard care","* General anesthesia (standardized induction): Propofol 2 mg\u002Fkg; Sufentanil 0.2 µg\u002Fkg; Ketamine 0.5 mg\u002Fkg; Dexamethasone 8 mg; neuromuscular blocker per anesthesiologist; maintenance with halogenated gases\n* Immediate postoperative analgesia at end of procedure: Paracetamol 1 g; Nefopam (Acupan) 20 mg; Parecoxib 40 mg\n* Postoperative analgesia regimen: Paracetamol 1 g ×4\u002Fday; Celecoxib 100 mg ×2\u002Fday; add Nefopam 30 mg ×3\u002Fday for moderate pain; morphine (Actiskenan) 5-10 mg every 4-6 h for severe pain (per numeric pain score thresholds)",[9,16],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"ropivacaine","1 Drug: Ropivacaine (laparoscopic port-site infiltration, surgical closure)\n\n* Timing: at surgical closure (end of surgery), performed by surgeon\n* Concentration: 2 mg\u002FmL\n* Volume: up to 20 mL (maximum)\n* Technique: deep musculo-aponeurotic layers\n* Ropivacaine plasma sampling: 30 min, 2 h, and 6 h after infiltration",[9,16],{"type":23,"name":33,"description":34,"armGroupLabels":35,"otherNames":27},"Lidocaine (intravenous infusion, perioperative)","* Start: at induction of general anesthesia\n* Loading dose (bolus): 1.5 mg\u002Fkg IV, based on actual body weight\n* Continuous infusion: 2 mg\u002Fkg\u002Fhour IV, based on actual body weight; for patients with BMI ≥ 30 kg\u002Fm², dosing based on adjusted body weight (Ideal body weight + 0.4 × \\[Actual - Ideal\\])\n* Stop: at surgical closure, at the time of wound infiltration with ropivacaine\n* Lidocaine plasma sampling (pharmacokinetics\u002Fsafety): 30 min after start of infusion; at surgical closure; 30 min after closure; 2 h and 6 h postoperatively",[16],[37],{"name":38,"role":39,"phone":40,"phoneExt":27,"email":41},"Ottilie Trocheris - Fumery, MD","CONTACT","33+322089108","fumery.ottilie@chu-amiens.fr",[43],{"facility":44,"status":27,"city":45,"state":27,"zip":46,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":27},"CHU Amiens","Amiens","80480","France",{"type":49,"coordinates":50},"Point",[51,52],2.3,49.9,{"lat":52,"lon":51},{"type":55,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100624828",false,"NCT07414706","Intravenous Lidocaine Plus Port-Site Ropivacaine for Recovery After Laparoscopic Surgery","Evaluation of Postoperative Recovery When Combining Intravenous Lidocaine With Ropivacaine Infiltrations in Colorectal Laparoscopic Surgery","LivQor","Inclusion Criteria:\n\n* Patient undergoing scheduled colorectal cancer surgery via laparoscopy.\n* Patient aged 18 years or older.\n* Informed consent obtained and signed.\n* Affiliation to a social security system.\n\nExclusion Criteria:\n\n* Allergy or contraindication to lidocaine or ropivacaine.\n* Allergy or contraindication to paracetamol, nefopam ketamine, propofol, dexamethasone, sufentanil, Celebrex or parecoxib, morphine derivatives, and colorectal surgery by laparotomy\n* Colorectal surgery with a non-cancerous indication.\n* Chronic preoperative pain (defined as persistent pain for more than 3 months).\n* Preoperative use of opioids or opioid derivatives.\n* Patients with psychiatric disorders.\n* Patients for whom self-assessment of pain using a self-reported scale cannot be performed (non-communicative, non-French speaking, etc.).\n* Pregnant or breastfeeding women.\n* Patients under guardianship, curatorship, or legal protection.","ALL","18 Years",{"count":66,"type":67},182,"ESTIMATED","INTERVENTIONAL",[70],"PHASE3","This randomized controlled trial evaluates whether perioperative intravenous lidocaine infusion, combined with port-site ropivacaine infiltration, improves postoperative recovery after laparoscopic abdominal surgery. Participants will be assigned 1:1 to receive either intravenous lidocaine during surgery plus ropivacaine infiltration at surgical closure, or ropivacaine infiltration alone. The primary endpoint is postoperative quality of recovery measured by the QoR-15 questionnaire. Secondary endpoints include postoperative pain and opioid consumption, as well as plasma lidocaine and ropivacaine concentrations to assess systemic exposure and safety.",[73,74,75,76],"Intravenous Lidocaine","Laparoscopic Surgery","Post Operative Recovery","Local Anaesthetic Systemic Toxicity",[78,79,80,81],"Intravenous lidocaine","laparoscopic surgery","post operative recovery","local anaesthetic systemic toxicity","NOT_YET_RECRUITING","2026-02-12",{"date":85,"type":86},"2026-02-17","ACTUAL",{"date":88,"type":67},"2026-03",{"date":90,"type":67},"2028-09",{"name":5,"class":6},1]